Your browser doesn't support javascript.
loading
Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice.
DA Costa, Rui M Gil; Araújo, Rita; Santos, Joana M O; Fernandes, Mara; Neto, Tiago; Sousa, Hugo; Ribeiro, Joana; Bastos, Margarida M S M; Oliveira, Paula A; Carmo, Diogo; Casaca, Fátima; Silva, Sandra; Lopes, Carlos; Medeiros, Rui.
Afiliación
  • DA Costa RMG; Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal rmcosta@fe.up.pt.
  • Araújo R; LEPABE, Faculty of Engineering, University of Porto, Porto, Portugal.
  • Santos JMO; Center for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Tras-os-Montes and Alto Douro (UTAD), Vila Real, Portugal.
  • Fernandes M; Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal.
  • Neto T; ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal.
  • Sousa H; Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal.
  • Ribeiro J; ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal.
  • Bastos MMSM; Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal.
  • Oliveira PA; FMUP, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Carmo D; LPCC, Research Department Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro-Nucleo Regional do Norte), Porto, Portugal.
  • Casaca F; Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal.
  • Silva S; Center for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Tras-os-Montes and Alto Douro (UTAD), Vila Real, Portugal.
  • Lopes C; ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal.
  • Medeiros R; Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal.
Anticancer Res ; 37(6): 2913-2918, 2017 06.
Article en En | MEDLINE | ID: mdl-28551628
BACKGROUND/AIM: Human papillomavirus type 16 (HPV16) induces various types of cancer in several locations. Microenvironmental microRNAs (miRNAs) such as miRNA-146a and miRNA-150 regulate cancer-associated inflammation and are involved in HPV-induced carcinogenesis. We studied the effects of celecoxib on the expression of these two miRNAs in HPV16-induced lesions. MATERIALS AND METHODS: Female transgenic (HPV16+/-) and wild-type (HPV16-/-) mice were administered 75 mg/kg/day celecoxib orally (treatment groups) or placebo (control groups) for four weeks. Skin samples were classified histologically, or used for miRNA analysis by quantitative real-time PCR. RESULTS: HPV16+/- mice showed higher miRNA-146a and miRNA-150 expression levels compared to wild-type animals. Celecoxib further increased miRNA-150 (p<0.05) and miRNA-146a levels in treated animals. Celecoxib-treated HPV16+/- animals also showed reduced incidence of epidermal dysplasia and reduced inflammation, compared to untreated mice. CONCLUSION: In this model, celecoxib may be able to regulate tumour-associated inflammation, through mechanisms involving the regulation of miRNA-146a and miRNA-150.
Asunto(s)
Palabras clave
Buscar en Google
Base de datos: MEDLINE Asunto principal: Lesiones Precancerosas / MicroARNs / Papillomavirus Humano 16 / Inhibidores de la Ciclooxigenasa 2 / Celecoxib Idioma: En Revista: Anticancer Res Año: 2017 Tipo del documento: Article
Buscar en Google
Base de datos: MEDLINE Asunto principal: Lesiones Precancerosas / MicroARNs / Papillomavirus Humano 16 / Inhibidores de la Ciclooxigenasa 2 / Celecoxib Idioma: En Revista: Anticancer Res Año: 2017 Tipo del documento: Article